Literature DB >> 10098339

An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis.

J M Bradley1, E S Wallace, J S Elborn, J L Howard, M P McCoy.   

Abstract

BACKGROUND: This retrospective audit was undertaken to compare the efficacy of home intravenous (i.v.) antibiotic therapy, hospital i.v. antibiotic therapy and a combination of these 2 approaches, as determined by spirometric measures of lung function in cystic fibrosis (CF) patients, each with an acute respiratory exacerbation.
METHODS: Pulmonary function, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow rate between 25 per cent and 75 per cent of vital capacity (FEF25-75), and peak expiratory flow rate (PEFR) were compared between groups at the beginning and at the end of an IV antibiotic course.
RESULTS: Treatment of exacerbations resulted in a significant improvement (p < 0.05) in lung function irrespective of where patients were treated. The percentage improvement in FEV1, FVC, and FEF25-75, were significantly greater in patients treated in hospital compared to those who had home i.v. treatment (p < 0.05).
CONCLUSION: Hospital i.v. antibiotic therapy resulted in greater improvements in FEV1, FVC and FEF25-75 than home i.v. antibiotic therapy in CF patients with an acute respiratory infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098339     DOI: 10.1007/bf02939576

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  13 in total

1.  Five- to seven-year course of pulmonary function in cystic fibrosis.

Authors:  M Corey; H Levison; D Crozier
Journal:  Am Rev Respir Dis       Date:  1976-12

2.  Antibiotic therapy in cystic fibrosis: evaluation of clinical trials.

Authors:  A L Smith
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

3.  The effect of a comprehensive, intensive inpatient treatment program on lung function and exercise capacity in patients with cystic fibrosis.

Authors:  J A Alison; P M Donnelly; M Lennon; S Parker; P Torzillo; C Mellis; P T Bye
Journal:  Phys Ther       Date:  1994-06

4.  Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects.

Authors:  J M Wolter; S D Bowler; P J Nolan; J G McCormack
Journal:  Eur Respir J       Date:  1997-04       Impact factor: 16.671

5.  Home intravenous antibiotic treatment of patients with cystic fibrosis.

Authors:  B Strandvik; L Hjelte; A S Malmborg; B Widén
Journal:  Acta Paediatr       Date:  1992-04       Impact factor: 2.299

6.  Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis.

Authors:  R J Winter; R J George; S J Deacock; C D Shee; D M Geddes
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

7.  Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis.

Authors:  M N Pond; M Newport; D Joanes; S P Conway
Journal:  Eur Respir J       Date:  1994-09       Impact factor: 16.671

8.  Cystic fibrosis: current survival and population estimates to the year 2000.

Authors:  J S Elborn; D J Shale; J R Britton
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

9.  Home intravenous antibiotic treatment in cystic fibrosis.

Authors:  J Gilbert; T Robinson; J M Littlewood
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

10.  Cystic fibrosis, intravenous antibiotics, and home therapy.

Authors:  L J Hammond; S Caldwell; P W Campbell
Journal:  J Pediatr Health Care       Date:  1991 Jan-Feb       Impact factor: 1.812

View more
  7 in total

1.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

2.  Changes in Pulmonary Function and Controlled Ventilation-High Resolution CT of Chest After Antibiotic Therapy in Infants and Young Children with Cystic Fibrosis.

Authors:  Shahid I Sheikh; Frederick R Long; Robert Flucke; Nancy A Ryan-Wenger; Don Hayes; Karen S McCoy
Journal:  Lung       Date:  2015-03-12       Impact factor: 2.584

3.  Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.

Authors:  G Steinkamp; B Wiedemann
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

4.  Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit.

Authors:  E A Chrysochoou; E Hatziagorou; F Kirvassilis; J Tsanakas
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

5.  Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis.

Authors:  J Thornton; R Elliott; M P Tully; M Dodd; A K Webb
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

Review 6.  Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

Authors:  E D Mitchell; C Czoski Murray; D Meads; J Minton; J Wright; M Twiddy
Journal:  BMJ Open       Date:  2017-04-20       Impact factor: 2.692

7.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.